Year Founded
2018
Ownership
Private
Employees
~50
Therapeutic Areas
Neurology
Stage
Phase 2
Modalities
Small molecule

Nido Biosciences General Information

Lead candidate NIDO-361 in Phase 2 for SBMA with completed enrollment of 54 patients. Study evaluating changes in muscle volume and functional outcomes.

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

NIDO-361
Phase 2
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Nido Biosciences's pipeline data

Book a demo

Key Partnerships

Eli Lilly and Company

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Nido Biosciences Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Nido Biosciences's complete valuation and funding history, request access »

Nido Biosciences Investors

5AM Ventures
Investor Type: Venture Capital
Holding: Minority
Abingworth
Investor Type: Venture Capital
Holding: Minority
Bessemer Venture Partners
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 6 investors. Get the full list »